Catalog No.
Product Name
Application
Product Information
Citations
-
11β-HSD1 Inhibitor
11β-HSD1-IN-10 is a potent inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), with an IC50 of 1.8 µM in human models. This compound is valuable for research on obesity, hyperglycemia, and cognitive impairment, providing insights into metabolic regulation and endocrine function. Its effectiveness makes it a useful tool for studying the role of glucocorticoid metabolism in various physiological and pathological conditions. -
11β-HSD Inhibitor
BMS-823778 is a selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1, which plays a crucial role in the regulation of cortisol metabolism. This compound has demonstrated potential in modulating glucose homeostasis and is primarily investigated for its applications in type 2 diabetes research. The inhibition of 11β-HSD1 by BMS-823778 may aid in exploring therapeutic strategies for metabolic disorders and related conditions. -
CYP17A1 Substrate
11-Ketoprogesterone (11KP4) serves as a substrate for the enzymes CYP17A1 and 11β-HSD2, facilitating the conversion to 21-deoxycortisone (21dE) and 21-deoxycortisol (21dF), both of which exhibit glucocorticoid activity. This compound is pivotal for studies examining steroidogenesis and adrenal hormone metabolism. It is utilized in research applications focusing on hormonal regulation and related disorders, providing insights into steroid hormone biosynthesis pathways. -
11β-HSD1 Inhibitor
MK-0736 is an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which plays a critical role in cortisol metabolism. This compound has been shown to lower blood pressure and is instrumental in research on type 2 diabetes and metabolic syndrome. Its application may support investigations into the therapeutic potential for managing metabolic disorders and related cardiovascular conditions. -
11β-HSD-1 Inhibitor
11β-HSD1-IN-6 is an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1), which catalyzes the conversion of active glucocorticoids such as cortisol to their inactive forms, 11-dehydrocorticosterone or cortisone. By inhibiting this enzyme, 11β-HSD1-IN-6 can modulate glucocorticoid availability and has potential applications in studies related to metabolic disorders, stress response, and associated therapeutic strategies. This compound serves as a valuable tool for investigating the biological roles of glucocorticoids and their implications in various diseases. -
11β-HSD1 Inhibitor
BMS-823778 hydrochloride is a selective and potent 11β-HSD1 inhibitor, exhibiting an IC50 of 2.3 nM against human 11β-HSD1. This compound plays a crucial role in regulating cortisol metabolism and glucose homeostasis, making it valuable in research related to metabolic disorders, obesity, and diabetes. It is particularly useful for studies investigating the effects of 11β-HSD1 inhibition on insulin sensitivity and related pathways. -
HSD1 Inhibitor
MK-0916 is a selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (HSD1). This compound induces mechanism-based activation of the hypothalamic-pituitary-adrenal axis, contributing to altered cortisol metabolism. MK-0916 is primarily utilized in research focused on type 2 diabetes and metabolic syndromes, providing insights into glucocorticoid regulation and potential therapeutic interventions. -
11β-HSD1 Inhibitor
UE2343 is a potent inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which plays a critical role in glucocorticoid metabolism. This compound is designed for oral administration and exhibits the ability to penetrate the blood-brain barrier. UE2343 is being researched for its potential therapeutic effects in the treatment of Alzheimer's disease, targeting neuroinflammation and cognitive decline associated with the condition. -
11β-HSD1 Inhibitor
BI-135585 hydrate is a selective and potent inhibitor of 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) with an IC50 of 13 nM. This compound demonstrates greater than 1000-fold selectivity over other hydroxysteroid dehydrogenases, making it a valuable tool for research. BI-135585 hydrate is primarily employed in studies related to type 2 diabetes, where modulation of glucocorticoid metabolism is of interest. -
11β-HSD1/11β-HSD2 Inhibitor
DG 381B is a selective inhibitor of 11β-HSD1 and 11β-HSD2, enzymes involved in the regulation of glucocorticoid metabolism. By inhibiting these enzymes, DG 381B plays a significant role in modulating cortisol levels, which can impact metabolic processes and inflammatory responses. This compound is valuable for research applications related to metabolic diseases, hypertension, and other conditions associated with glucocorticoid action. -
11β-HSD1 Inhibitor
MK-0736 hydrochloride is a potent and selective inhibitor of 11β-HSD1, a key enzyme involved in glucocorticoid metabolism. This compound has shown significant antihypertensive effects and is valuable for research into metabolic syndrome and related disorders. Clinical studies indicate that MK-0736 hydrochloride possesses a favorable safety profile, making it a promising candidate for further exploration in hypertension-related research. -
11β-HSD1 Inhibitor
INU-101 is a selective, orally active inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). It demonstrates potent inhibitory activity in liver microsomes from mouse, monkey, and human sources, effectively enhancing insulin sensitivity and reducing fasting blood glucose levels. This compound is applicable in research focused on metabolic diseases, particularly diabetes, making it a valuable tool for studying metabolic pathways and potential therapeutic strategies. -
11β-HSD1 Inhibitor
(R)-BMS-816336 is a selective inhibitor of the 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme. It demonstrates potent inhibitory activity with IC50 values of 14.5 nM for human, 50.3 nM for mouse, and 16 nM for cynomolgus monkey 11β-HSD1. This compound is applicable in research focused on metabolic disorders, obesity, and diabetes due to its role in modulating glucocorticoid metabolism. -
11β-HSD Inhibitor
Clofutriben (ASP3662) is a selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). By inhibiting this enzyme, Clofutriben plays a critical role in modulating cortisol metabolism, thereby influencing glucocorticoid signaling pathways. This compound is primarily utilized in research related to metabolic disorders, obesity, and stress response. Its applications include evaluating the therapeutic potential of targeting 11β-HSD1 in various disease models. -
11β-HSD Inhibitor
11β-HSD1-IN-16 is a selective inhibitor of the 11β-hydroxysteroid dehydrogenase HSD11B1, with an IC50 of 0.34 μM. This compound has key applications in research related to neuropathic pain, inflammatory pain, and occipital neuralgia. Its ability to modulate glucocorticoid metabolism makes it an important tool for understanding the role of 11β-HSD in various pain pathways. -
11β-HSD1 Inhibitor
11β-HSD1-IN-15 is a selective inhibitor of 11β-hydroxysteroid dehydrogenase type I (11β-HSD1), effectively blocking the conversion of corticosterone to cortisol. By binding to the enzyme's active site, it serves as a valuable tool for investigating the role of 11β-HSD1 in various pathological conditions. This compound is particularly relevant for research on metabolic syndrome, obesity, cognitive decline, and type 2 diabetes, enabling insights into therapeutic strategies targeting these disorders. -
11β-HSD Inhibitor
11β-HSD1-IN-14 is a selective inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) with an IC50 of 74 nM for human HSD1 and 603 nM for HSD1 expressed in HEK293 cells. This compound demonstrates significant potential for modulating cortisol metabolism, making it relevant for research in metabolic disorders, obesity, and stress-related conditions. Its specificity supports studies aimed at elucidating the role of 11β-HSD1 in various physiological and pathological processes. -
11β-HSD1 Inhibitor
JTT-654 is a potent and selective inhibitor of 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1), exhibiting an IC50 of 4.65 nM for the human enzyme. This compound acts competitively against human recombinant 11β-HSD1 while demonstrating minimal inhibition of 11β-HSD2 (IC50 > 30 μM). JTT-654 has been shown to improve insulin resistance and alleviate non-obese type 2 diabetes by targeting 11β-HSD1 in adipose tissue and the liver, making it a valuable tool for studying metabolic disorders. -
11β-HSD1 Inhibitor
BVT-2733 hydrochloride is a selective, nonsteroidal inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). With an IC50 of 96 nM for the mouse enzyme, it exhibits lower potency against the human variant (IC50 of 3341 nM). This compound is valuable for investigating the role of 11β-HSD1 in the pathophysiology of arthritis and obesity-related conditions, providing insights into therapeutic strategies for these diseases. -
11β-HSD Inhibitor
BVT-3498 is a potent inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), a key enzyme in glucocorticoid metabolism. By selectively blocking 11β-HSD1 activity, BVT-3498 modulates local cortisol levels, which is critical for research into metabolic diseases and stress-related disorders. This compound serves as a valuable tool in elucidating the role of 11β-HSD1 in various physiological and pathological processes. -
15-PGDH Inhibitor
MF-DH-300 is a selective inhibitor of 15-PGDH, a key enzyme in the degradation of prostaglandins. By inhibiting this enzyme, MF-DH-300 enhances prostaglandin levels, which may have therapeutic implications in muscle disorders, such as spinal muscular atrophy (SMA). This compound is valuable for research focused on understanding the role of prostaglandins in muscle-related pathologies and developing potential interventions. -
15-PGDH Inhibitor
ML148 is a potent and selective inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), exhibiting an IC50 of 56 nM. This compound is particularly valuable for the investigation of prostaglandin signaling pathways, which play critical roles in inflammation, pain, and various physiological processes. ML148’s specificity and inhibitory capacity make it a crucial tool for exploring the modulation of prostaglandin metabolism in various biological contexts. -
15-PGDH Inhibitior
15-PGDH-IN-1 is a potent inhibitor of the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH) with an IC50 value of 3 nM against recombinant human 15-PGDH. This compound is orally active and is valuable for investigating the roles of 15-PGDH in tissue repair and regeneration processes. Its inhibitory action may facilitate research into therapeutic strategies targeting inflammation and cellular regeneration. -
15-PGDH Inhibitor
HW201877 is an effective and orally active inhibitor of 15-prostaglandin dehydrogenase (15-PGDH) with an IC50 value of 3.6 nM. This compound significantly increases PGE2 levels in A549 cells and has demonstrated notable efficacy in preclinical models of tissue injury and fibrosis. HW201877 is suitable for investigating inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF), and Crohn’s disease (CD). -
15-PGDH Inhibitor
15-PGDH-IN-4 is a potent inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), exhibiting an IC50 value of 1.2 nM against human 15-PGDH. This reagent is valuable for research into immune cell function and tissue regeneration, enabling the exploration of metabolic pathways and inflammatory processes. Its ability to modulate 15-PGDH activity makes it a critical tool for studies aimed at understanding and manipulating prostaglandin signaling. -
15-PGDH Inhibitor
(R)-SW033291 is a potent and high-affinity inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH). By inhibiting this enzyme, (R)-SW033291 significantly increases levels of prostaglandin E2 (PGE2) in bone marrow and other tissues. This compound has potential applications in research focused on tissue regeneration and the modulation of inflammatory responses associated with prostaglandin signaling. -
15-PGDH Inhibitor
MF-PGDH-008 is a selective inhibitor of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH). This compound plays a crucial role in modulating prostaglandin levels, offering significant potential in research focused on inflammation and cancer biology. Its ability to inhibit 15-PGDH makes it valuable for exploring therapeutic strategies aimed at enhancing prostaglandin signaling in various biomedical studies. -
15-PGDH Inhibitor
15-PGDH-IN-3 is a selective competitive inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH). This compound plays a critical role in regulating prostaglandin levels and can be utilized to study the modulation of inflammatory responses and cancer progression. Its inhibition of 15-PGDH may have implications in various research applications, including pain management and the investigation of therapeutic targets in oncology. -
15-PGDH Inhibitor
CAY10397 is a selective and orally bioavailable inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH). It effectively inhibits the production of endogenous metabolites dependent on 15-PGDH, and it has been shown to block selenium-dependent protective mechanisms in inflammation. CAY10397 is primarily utilized in research related to colitis and other inflammatory conditions, providing insights into the role of 15-PGDH in disease pathology. -
15-PGDH Inhibitor
15-epi-PGE1 is a stereoisomer of Prostaglandin E1 that functions as a non-competitive inhibitor of human placental 15-Hydroxyprostaglandin dehydrogenase (15-PGDH). With an IC50 value of 170 μM, this compound exhibits inhibitory activity that can be utilized in studies of prostaglandin metabolism. Research applications may include investigations into the roles of prostaglandins in various physiological and pathological processes. -
15-PGDH Inhibitor
15-PGDH-IN-2 is a potent inhibitor of 15-PGDH, displaying an IC50 value of 0.274 nM. This compound is valuable for researching biological processes such as hair loss, bone formation, gastric ulcer healing, and dermal wound healing. Its ability to modulate 15-PGDH activity makes it a useful tool in studying pathways associated with these conditions. -
HSD17B13 Inhibitor
BI-3231 is a potent and selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating IC50 values of 1 nM and 13 nM for human and mouse HSD17B13, respectively. This compound is valuable for research into nonalcoholic steatohepatitis (NASH) and various liver disorders, facilitating the investigation of HSD17B13's role in lipid metabolism and liver function. Its selective inhibition offers a promising avenue for understanding and potentially treating these conditions. -
AKR1C3 Inhibitor
AKR1C3-IN-4 is a potent and selective inhibitor of aldo-keto reductase 1C3 (AKR1C3), exhibiting an IC50 value of 0.56 μM. This compound is particularly relevant for investigations into castrate-resistant prostate cancer (CRPC), where AKR1C3 plays a crucial role in tumor progression and hormone regulation. Its mechanism facilitates the exploration of therapeutic strategies targeting metabolic pathways in cancer research. -
17β-HSD1 Inhibitor
17β-HSD1-IN-1 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), exhibiting IC50 values of 5.6 nM for 17β-HSD1 and 3155 nM for 17β-HSD2. This compound plays a crucial role in modulating estrogen levels and is pertinent for research focused on non-small cell lung cancer (NSCLC). Its specificity enables targeted studies into the enzymatic pathways associated with hormone-driven tumorigenesis. -
Non-alcoholic steatohepatitis
Rapirosiran sodium is an N-acetylgalactosamine-conjugated small-interfering RNA that specifically targets hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) mRNA in the liver. It is associated with a reduction in the risk of chronic liver diseases due to loss-of-function variants in the HSD17B13 gene. This reagent is particularly valuable for research focused on non-alcoholic steatohepatitis, facilitating the exploration of therapeutic strategies targeting liver metabolism and inflammation. -
Non-alcoholic steatohepatitis
Rapirosiran is an N-acetylgalactosamine-conjugated small interfering RNA that specifically targets mRNA of hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) in the liver. Inhibition of HSD17B13 via Rapirosiran is associated with a reduced risk of chronic liver disease. This reagent is valuable for investigating the mechanisms of non-alcoholic steatohepatitis and exploring potential therapeutic approaches. -
AKR1C3 Inhibitor
S07-1066 is a selective inhibitor of aldo-keto reductase 1C3 (AKR1C3) that enhances the cytotoxic effects of doxorubicin (DOX). By inhibiting the AKR1C3-mediated reduction of DOX, S07-1066 effectively reverses drug resistance in cells that overexpress this enzyme. This compound is valuable for research applications investigating chemotherapy resistance and potential adjuvant therapies in cancer treatment. -
17β-HSD10 Inhibitor
17β-HSD10-IN-1 is a potent inhibitor of 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10), exhibiting oral bioavailability and effective blood-brain barrier penetration. This compound is characterized by a selective mechanism of action that minimizes off-target effects on mitochondria, along with a favorable safety profile devoid of cytotoxic or neurotoxic effects. It is suitable for research applications focused on disorders related to steroid metabolism and neurodegenerative diseases. -
HSD17B1 Inhibitor
Linustedastatum is an orally active inhibitor of hydroxysteroid 17-beta dehydrogenase 1 (HSD17B1). This compound exhibits significant biological activity by modulating the biosynthesis of estrogens, making it a valuable tool for research applications related to endometriosis. Its mechanism of action provides insights into hormonal pathways and potential therapeutic targets in gynecological disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-2 is a selective inhibitor of HSD17B13, demonstrating human IC50 values of 0.18 μM with β-estradiol and 0.25 μM with Leukotriene B4. This compound binds to the active site of HSD17B13 in an NAD+-dependent manner, interacting with the bound NAD+ cofactor to stabilize the HSD17B13 protein and prevent its aggregation. HSD17B13-IN-2 effectively reduces the conversion of β-estradiol to estrone in cellular assays, making it a valuable tool for investigating nonalcoholic fatty liver disease and related metabolic disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-3 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting IC50 values of 0.38 μM and 0.45 μM in biochemical assays using β-estradiol and Leukotriene B4 (LTB4) as substrates, respectively, in the presence of NAD+ as a cofactor. This compound is useful for studying the role of HSD17B13 in steroid metabolism and has potential applications in research related to metabolic disorders and inflammatory conditions. However, it exhibits low cell penetration, which may limit its use in certain cellular assays. -
HSD17B13 Inhbitor
HSD17B13-IN-9 is a selective inhibitor of 17β-Hydroxysteroid dehydrogenases 13 (HSD17B13), exhibiting an IC50 of 0.01 μM against 50 nM HSD17B13. This compound plays a significant role in the investigation of nonalcoholic fatty liver diseases (NAFLD) by modulating steroid metabolism and related pathways. Its potent inhibitory effects make it a valuable tool for research into hepatic lipid metabolism and associated disorders. -
HSD17B13 Inhbitor
HSD17B13-IN-8 is an inhibitor of 17β-hydroxysteroid dehydrogenases (HSD17B13), demonstrating potent inhibitory activity with IC50 values of less than 0.1 μM for estradiol and less than 1 μM for LTB3. This compound is primarily utilized in research related to nonalcoholic fatty liver disease (NAFLD), allowing for deeper investigation into the metabolic pathways involved in liver disorders. -
Anticancer Agent
Odafosfamide is a selective prodrug bis-alkylating agent that is activated by aldehyde-keto reductase 1C3 (AKR1C3). It exhibits potent cytotoxicity in cell lines that express high levels of AKR1C3, demonstrating significant antitumor activity in various cancers, including liver cancer, non-small cell lung cancer, and leukemia. This compound is suitable for use in cancer research to investigate mechanisms of action and therapeutic potential in malignancies characterized by elevated AKR1C3 expression. -
HSD17B13 Inhibitor
HSD17B13-IN-10 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of 0.01 μM. This compound is valuable in researching liver diseases by modulating steroid metabolism and influencing lipid and glucose homeostasis. Its selective inhibition makes it a critical tool for studying the pathogenic mechanisms underlying hepatic disorders. -
HSD17B13 Inhbitor
HSD17B13-IN-43 is a selective inhibitor of 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in nonalcoholic fatty liver disease (NAFLD) and related metabolic disorders. Its ability to modulate steroid metabolism makes it a significant tool for research into liver function and disease mechanisms. -
HSD17B13 Inhibitor
HSD17B13-IN-41 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound demonstrates potential in modulating pathways associated with liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Its application in research can aid in understanding the underlying mechanisms of these diseases and support the development of novel therapeutic strategies. -
HSD17B13 Inhibitor
HSD17B13-IN-29 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is a valuable tool for research into liver diseases, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI), as well as metabolic and cardiovascular disorders. Its selectivity for HSD17B13 positions it as a significant reagent for investigating therapeutic strategies targeting these conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-49 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research into various liver-related conditions, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as studies on drug-induced liver injury (DILI). Its inhibition of HSD17B13 may provide insights into potential therapeutic strategies for metabolic and cardiovascular disorders linked to liver dysfunction. -
HSD17B13 Inhibitor
HSD17B13-IN-69 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an impressive IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research into liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its potent inhibition profile makes HSD17B13-IN-69 a crucial tool for exploring therapeutic strategies and understanding disease mechanisms.
